A novel mouse model offers definitive evidence that a single inhibitory receptor family governs the critical natural killer cell functions of licensing and missing-self.

Just a few months after dumping its lead asset and cutting its workforce in half, Cargo Therapeutics is jettisoning even more ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...

A novel strategy using lipid nanoparticles to reprogram liver immunity shows promise in generating antitumor responses ...

Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet ...

Discover the newly identified proteins to predict ICANS, improving the safety of CAR-T cell therapy by identifying high-risk ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...